Lupin Pharmaceuticals has finally received the approval from the US Food and Drug Administration to market its oral contraceptive pills in the United States.
The pills are a generic version of Yasmin, manufactured by Bayer Healthcare, and allows Lupin to carve a slice of the oral contraceptive market which has been growing at a rate of nearly 10 percent every year in the United States.
AdvertisementConservative estimates by analysts predict that Lupin will be able to gain a 10 percent market share for the pills, potentially earning them over $27 million in annual sales.
The Mumbai-based drug maker released a statement saying, "Lupin will be marketing its Drospirenone and Ethinyl Estradiol tablets USP in a wallet pack of 28 tablets consisting of 21 yellow active tablets, each containing 3 mg Drospirenone and 0.03 mg Ethinyl Estradiol, and 7 white inert tablets."
P Abbott Launches Bioresorbable Vascular Scaffold in India Pop Singers Who Try to Make a Success on Own Face Risk of Premature Death M
You May Also Like